Engineered Probiotic Bacteria Deliver Arthritis-Fighting Peptide Orally as Effectively as Injection

Researchers constructed a plasmid for inducible secretion of iberiotoxin and transformed it into probiotic L. reuteri to create LrIbTX. The engineered bacteria were characterized for growth rate and fecal recovery after oral gavage. Systemic IbTX delivery was confirmed using a competitive binding assay in rat serum. Efficacy was tested in the collagen-induced arthritis (CIA) rat model, comparing oral LrIbTX to injected IbTX and control bacteria. Outcomes included clinical joint scores, histologic inflammation, bone density, anti-collagen antibodies, and anti-IbTX antibodies. A delayed-type hypersensitivity model was also used.

One of the biggest challenges in peptide therapeutics is oral delivery — most peptides are destroyed by stomach acid and digestive enzymes, forcing patients to rely on injections. This study demonstrates a fundamentally new approach: using engineered probiotic bacteria as living factories that produce and secrete therapeutic peptides directly in the gut, where they can be absorbed systemically. If this platform generalizes to other peptides, it could transform how peptide drugs are delivered.

This study represents the convergence of two hot fields: engineered probiotics and peptide therapeutics. The demonstration that a gut bacterium can produce a peptide that reaches therapeutic levels in the bloodstream is a proof of concept with broad implications. Many peptide drugs — from insulin to GLP-1 agonists to antimicrobial peptides — currently require injection. An oral probiotic delivery platform could dramatically improve patient compliance and reduce healthcare costs for peptide-based treatments across many diseases.

This is a preclinical study in rats, and oral-to-systemic peptide delivery through engineered bacteria faces significant challenges in translation to humans, including differences in gut physiology, immune responses, and regulatory hurdles for live biotherapeutics. The specific serum levels of IbTX achieved were not quantified with standard pharmacokinetic methods. Long-term safety of chronically administering engineered bacteria that produce bioactive peptides in the gut is unknown. The collagen-induced arthritis model, while standard, does not fully recapitulate human rheumatoid arthritis.